Tricyclic antidepressants explained

What tricyclic antidepressants are

Tricyclic antidepressants, usually shortened to TCAs, are a class of medication named after their chemical structure. They have a three-ring backbone, which is where the "tricyclic" part comes from. That structure is the accident of chemistry from which the whole class grew, and it's why the name describes what the molecules look like rather than what they do.

TCAs treat depression, and they treat quite a few other things. At low doses they're used for chronic pain and nerve pain. Amitriptyline is one of the most commonly prescribed medications in the world for migraine prevention. Clomipramine is one of the more effective options for OCD. Nortriptyline and desipramine are chosen when the goal is fewer side effects. Doxepin at very low doses is used for insomnia.

The TCAs covered on PsychiatryRx are amitriptyline, nortriptyline, imipramine, desipramine, clomipramine, doxepin, protriptyline, trimipramine, amoxapine, and maprotiline. Maprotiline is technically a tetracyclic, four rings rather than three, but it acts so much like a TCA that it usually travels with the group.

How they work

Nerve cells in the brain pass messages using chemical messengers. Two of the ones that matter for mood are serotonin and norepinephrine. A cell releases a messenger into the small gap between cells, the next cell picks up the signal, and the releasing cell reabsorbs much of what it sent. That reabsorption is called reuptake. TCAs slow the reuptake of both serotonin and norepinephrine, so more of each stays available between cells. In that sense, TCAs are cousins of SNRIs. They were doing what SNRIs do, decades earlier, but without the selectivity.

The trouble is that TCAs don't stop at serotonin and norepinephrine. They also block acetylcholine receptors (muscarinic), histamine H1 receptors, and alpha-1 adrenergic receptors. Each of those actions produces a familiar set of problems. Blocking acetylcholine causes dry mouth, constipation, blurry vision, urinary retention, and confusion in older adults. Blocking histamine causes sedation and weight gain. Blocking alpha-1 causes lightheadedness when standing up. Those side effects aren't a bug on top of the antidepressant effect. They're baked into the same molecule.

TCAs also affect the heart's electrical conduction. That's the reason overdose is dangerous, and it's the reason an ECG is often checked before starting one in someone older or in someone with heart history.

The individual TCAs differ in how strongly they lean toward serotonin versus norepinephrine and in how much of the other receptor activity they carry. That's what shapes the choice between them.

How the class developed

The first TCA, imipramine, was discovered in the 1950s while researchers were looking for something else. Chemists at Geigy were testing chlorpromazine-like compounds for schizophrenia. Imipramine didn't help psychosis, but a Swiss psychiatrist named Roland Kuhn noticed that some patients on it, particularly those with depression, brightened. That observation opened the whole field of drug treatment for depression.

Other TCAs followed through the 1960s and 1970s. Amitriptyline, nortriptyline, desipramine, doxepin, clomipramine, and others joined the group. For roughly thirty years, TCAs and the MAOIs were what psychiatry had for depression.

SSRIs arrived in the late 1980s. Fluoxetine reached the U.S. market in 1988, and the SSRIs and SNRIs that followed pushed TCAs out of the first-line role. It wasn't because TCAs stopped working. On effectiveness, TCAs and SSRIs are broadly comparable, and some meta-analyses give a slight edge to TCAs for hospitalized or severe depression. The newer drugs won on safety, tolerability, and overdose risk, which matters a lot in a population being treated for depression. TCAs stayed in use for the roles that turned out to be theirs alone, or nearly so, including chronic pain, nerve pain, migraine prevention, and OCD.

What they treat

TCAs are used for several conditions.

• Major depressive disorder, often after SSRIs and SNRIs haven't worked well enough, or in situations where a prescriber wants a specific TCA property.
• Chronic pain conditions, especially neuropathic pain such as diabetic neuropathy and postherpetic neuralgia. Nortriptyline and amitriptyline are the ones most used here.
• Migraine prevention. Amitriptyline is a mainstay.
• Insomnia at low doses, most often doxepin at 3 mg or 6 mg.
• Obsessive-compulsive disorder. Clomipramine is the TCA most used for OCD and is one of the more effective medications for it.
• Enuresis in children (bedwetting), for which imipramine has an FDA approval that dates back decades.
• Panic disorder. Imipramine was one of the first medications shown to help panic attacks.

Prescribers also use TCAs off-label for other conditions, meaning for a purpose the label doesn't formally list even though evidence and practice support it. Interstitial cystitis and irritable bowel syndrome are two examples.

Individual medications in this class

• Amitriptyline (Elavil). One of the most widely used TCAs. Strong action on both serotonin and norepinephrine, and heavy on the anticholinergic and sedating side effects. Widely used for chronic pain, migraine prevention, and depression when a sedating option is wanted.
• Nortriptyline (Pamelor). The active breakdown product of amitriptyline, and generally better tolerated. Fewer anticholinergic effects, less sedation, less orthostatic hypotension. Serum levels are useful, and the therapeutic window is roughly 50 to 150 ng/mL.
• Imipramine (Tofranil). The original TCA. Used for depression, panic disorder, and childhood enuresis.
• Desipramine (Norpramin). The active breakdown product of imipramine. The most norepinephrine-selective TCA on the market, and one of the better tolerated for anticholinergic burden.
• Clomipramine (Anafranil). The most serotonergic TCA, and the one used for OCD. It carries more side effects than the SSRIs typically used for OCD, but it's often more effective, so it stays in the picture for OCD that hasn't responded enough.
• Doxepin (Silenor, Sinequan). Used for depression at standard doses. At very low doses (3 mg or 6 mg) it's approved for insomnia, where the antihistamine effect does the work.
• Protriptyline (Vivactil). Less sedating than most TCAs, sometimes described as activating. Used less often now.
• Trimipramine (Surmontil). Sedating, with a side-effect profile similar to amitriptyline. Rarely used.
• Amoxapine (Asendin). A TCA with some antipsychotic-like activity, which means it carries a small risk of movement side effects that other TCAs don't. Not commonly used.
• Maprotiline (Ludiomil). Technically a tetracyclic, but grouped here. Norepinephrine-selective. Carries a higher seizure risk than most TCAs, especially at higher doses. Not commonly used.

Common side effects across the class

The TCAs share a familiar side-effect set, and most of it comes from the receptor activity beyond serotonin and norepinephrine.

• Dry mouth, constipation, blurry vision, and difficulty urinating. These are the anticholinergic effects. They're often worst in the first weeks and lessen with time.
• Sedation and daytime drowsiness. This is the histamine H1 effect. Some TCAs, like amitriptyline and doxepin, are quite sedating. Others, like desipramine and protriptyline, less so.
• Lightheadedness on standing, called orthostatic hypotension. This is the alpha-1 effect. It matters especially in older adults, who are more likely to fall.
• Weight gain over months of use.
• Sexual side effects, including reduced desire and delayed orgasm. Less prominent than with SSRIs for some people but still real.
• Sweating.
• Increased heart rate.
• Fine tremor.
• Confusion or memory problems, especially in older adults. This is again the anticholinergic effect and it's the reason the American Geriatrics Society Beers Criteria list most TCAs as medications to avoid in older adults when possible.

Nortriptyline and desipramine are the TCAs usually chosen when someone needs a TCA but the side-effect burden matters. They carry the lightest anticholinergic load.

Serious warnings across the class

The concerns that shape TCA prescribing.

• Overdose risk. This is the single biggest reason TCAs aren't first-line for depression anymore. They have a narrow therapeutic index, meaning the toxic dose isn't very far above the therapeutic dose. In overdose, TCAs can cause dangerous heart rhythm problems, seizures, and death. A typical outpatient supply can be lethal.
• ECG changes. TCAs can prolong the QRS interval and the QT interval on the ECG. Baseline and follow-up ECGs are often ordered, especially in older adults, in people with heart disease, or at higher doses.
• The antidepressant boxed warning about a possible increase in suicidal thoughts in people under 25, especially in the first weeks of treatment. This applies to TCAs as it does to other antidepressants.
• Serotonin syndrome. TCAs raise serotonin, and combining them with other serotonergic medications, especially MAOIs, can trigger a dangerous reaction. A 14-day gap is required between stopping an MAOI and starting a TCA, and vice versa.
• Seizure risk. TCAs can lower the seizure threshold, and the risk goes up at higher doses. Maprotiline has more of this than the others.
• Anticholinergic burden. This isn't a single side effect but the accumulated effect of anticholinergic medications on cognition, especially in older adults. It's linked to falls, delirium, and possibly to dementia risk with long-term high burden.
• Angle-closure glaucoma. The anticholinergic action can trigger an attack in people at risk.
• Discontinuation symptoms. Stopping abruptly can cause flu-like feelings, dizziness, nausea, and sleep disruption. A gradual taper matters here too.

What tips the choice within the class

Once a prescriber and patient agree that a TCA is worth trying, the choice usually comes down to a few practical questions.

Tolerability. If side-effect burden is a concern, nortriptyline and desipramine are usually first because they carry less anticholinergic load, less sedation, and less orthostatic hypotension than amitriptyline, doxepin, or imipramine.

Serum levels. Nortriptyline is unusual in that its blood level lines up reasonably well with its effect, and the therapeutic window is roughly 50 to 150 ng/mL. Desipramine and imipramine also have levels that can be measured. When dose-response is uncertain, a level can help.

What the medication is for. For depression alone, tolerability leads. For migraine prevention or chronic pain, amitriptyline and nortriptyline are the ones with the most evidence and use. For OCD, clomipramine has evidence the other TCAs don't. For insomnia, low-dose doxepin has an FDA approval other TCAs don't.

Whether sedation is wanted. Amitriptyline and doxepin are sedating, which can be a feature for someone who isn't sleeping. Desipramine and protriptyline are less sedating. That distinction shapes the choice more than raw effectiveness for many people.

Heart history. In someone with known heart disease or conduction abnormalities, a prescriber may avoid TCAs, choose the least cardiotoxic option, or check ECGs during treatment.

Other medications. TCAs are broken down by liver enzymes and are subject to interactions. That factors in when someone is on several medications.

Common questions

Are TCAs still worth using? Yes, for the right situations. TCAs aren't first-line for depression anymore because SSRIs and SNRIs are safer and easier to tolerate. They're still first-line, or close to it, for a few things: migraine prevention (amitriptyline), certain nerve pain conditions (amitriptyline, nortriptyline, desipramine), OCD when SSRIs haven't been enough (clomipramine), and low-dose sleep (doxepin). For depression that hasn't responded to newer options, a TCA is a reasonable next step.

Why are TCAs dangerous in overdose? Because they affect heart conduction, they can cause dangerous rhythm problems in overdose, and because they lower the seizure threshold, high doses can cause seizures. The therapeutic index is narrow, meaning the amount that helps and the amount that harms aren't far apart. A one-month supply can be lethal. That's why prescribers are careful with TCAs in people at high risk of suicide, and why smaller supplies are sometimes dispensed.

What is the therapeutic level for nortriptyline? Roughly 50 to 150 ng/mL. Levels below that range are often not enough. Levels above 150 ng/mL don't add benefit and add side effects. Levels are drawn as a trough, meaning just before the next dose, and after at least five days on a stable dose so the level has stabilized.

Why do TCAs cause so many side effects? They act on many systems at once. Beyond serotonin and norepinephrine, they block acetylcholine receptors (dry mouth, constipation, blurry vision, urinary retention, confusion), histamine H1 receptors (sedation, weight gain), and alpha-1 receptors (lightheadedness). SSRIs were designed to be selective, meaning to hit serotonin and mostly leave the other systems alone, and that's why they're better tolerated.

How long do TCAs take to work? For depression, four to six weeks for the fuller effect, sometimes up to eight. For migraine prevention, four to eight weeks. For nerve pain, one to four weeks, often at lower doses than the ones used for depression. Side effects usually arrive before the benefit, and doses are typically titrated up slowly to help the body adjust.

Sources

This guide draws on current prescribing information and public health references. It's reviewed for clinical accuracy and updated as guidance changes. This is educational content, not medical advice, and it isn't a substitute for a conversation with your own prescriber.

1. U.S. Food and Drug Administration. Prescribing information.
2. MedlinePlus, U.S. National Library of Medicine.
3. National Institute of Mental Health. Mental health medications.
4. American Psychiatric Association. Practice guideline for the treatment of patients with major depressive disorder.
5. American Geriatrics Society Beers Criteria for Potentially Inappropriate Medication Use in Older Adults.